29 September 2026
Feng Wang PhD MD; CSCO 2026: Progress and Prospects of New Drug Research for Colorectal Cancer: The View from China
Audio Journal of Oncology Podcast
About
JINAN, China—The 2026 Annual Meeting of the Chinese Society of Clinical Oncology, with more than 40 000 cancer clinicians attending, heard evidence from clinical trial findings and new science bringing great hope for the treatment of colorectal cancer.
The era of targeted precision medicine for colorectal cancer had truly arrived, delegates heard, with a long list of potential targets identified by genetic testing, and an impressive range of promising agents to match them to treat cancer in new and more effective ways.
In an abstract entitled: “Progress and Prospects of New Drug Research for Colorectal Cancer”, the latest state of the art in colorectal cancer research was assessed by Feng Wang PhD MD, Director of Medical Oncology at Sun Yat-sen University Cancer Center, in Guangzhou, China. Afterwards, she talked with our reporter, Peter Goodwin:
The era of targeted precision medicine for colorectal cancer had truly arrived, delegates heard, with a long list of potential targets identified by genetic testing, and an impressive range of promising agents to match them to treat cancer in new and more effective ways.
In an abstract entitled: “Progress and Prospects of New Drug Research for Colorectal Cancer”, the latest state of the art in colorectal cancer research was assessed by Feng Wang PhD MD, Director of Medical Oncology at Sun Yat-sen University Cancer Center, in Guangzhou, China. Afterwards, she talked with our reporter, Peter Goodwin: